Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Half of CLL patients who relapse on ibrutinib harbour BTK/PLCG mutations

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.06.18
Views: 1893

Dr Lydia Scarfo - San Raffaele Scientific Institute, Milan, Italy

Dr Scarfo speaks with ecancer at EHA 23 about a multicentre international study which finds 50% of CLL patients who have received Brutons tyrosine kinase inhibitor ibrutinib in the course of their CLL treatment who relapse harbour mutations in BTK and associated PLCG2 genes.

She outlines the recruitment procedure and patient cohort, and implications of these findings for screening and treatment guidance.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

ONJ e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation